Time (hours) | Marker | False negatives (n)4-150 | Sensitivity (95% CI) | Specificity (95% CI) | NPV4-151 (95% CI) | PPV4-152 (95% CI) | Pretest probability4-153 |
---|---|---|---|---|---|---|---|
4 | Myoglobin | 10 | 54.6 (47.1 to 61.8) | 74.4 (67.4 to 80.4) | 92.4 (86.2 to 96.1) | 22.2 (13.1 to 35.2) | 11.8 |
8 | Myoglobin | 9 | 65.4 (58.2 to 71.9) | 71.2 (64.2 to 77.3) | 93.1 (86.9 to 96.6) | 25.8 (16.7 to 37.6) | 13.3 |
16 | Myoglobin | 8 | 70.4 (63.3 to 76.6) | 69.5 (62.4 to 75.8) | 93.4 (87.1 to 96.9) | 27.5 (18.3 to 39.2) | 14.1 |
24 | Myoglobin | 8 | 70.4 (62.8 to 77.0) | 65.3 (57.6 to 72.3) | 92.2 (84.7 to 96.3) | 27.5 (18.3 to 39.2) | 15.8 |
4 | CK-MBmass | 4 | 80.0 (73.4 to 85.4) | 92.1 (87.0 to 95.4) | 97.4 (93.2 to 99.2) | 55.2 (37.2 to 71.9) | 10.8 |
8 | CK-MBmass | 3 | 88.0 (82.4 to 92.0) | 91.9 (86.9 to 95.1) | 98.1 (94.2 to 99.5) | 61.1 (44.6 to 75.4) | 12.7 |
16 | CK-MBmass | 3 | 88.9 (83.3 to 92.8) | 90.6 (85.3 to 94.2) | 98.0 (93.7 to 99.5) | 61.5 (45.6 to 75.3) | 14.4 |
24 | CK-MBmass | 3 | 89.3 (83.2 to 93.4) | 87.9 (81.6 to 92.3) | 97.5 (92.3 to 99.3) | 61.0 (45.5 to 74.5) | 17.5 |
4 | MLC 1 | 6 | 75.0 (68.1 to 80.9) | 64.2 (56.9 to 71.0) | 94.6 (88.2 to 97.8) | 23.4 (15.2 to 34.1) | 12.7 |
8 | MLC 1 | 6 | 78.6 (72.1 to 83.9) | 61.1 (53.9 to 67.8) | 94.6 (88.1 to 97.8) | 24.7 (16.9 to 34.7) | 14.0 |
16 | MLC1 | 5 | 81.5 (75.0 to 86.5) | 56.5 (49.2 to 63.5) | 95.0 (88.3 to 98.2) | 22.9 (15.6 to 32.4) | 13.7 |
24 | MLC 1 | 5 | 81.5 (75.0 to 86.6) | 52.5 (45.1 to 59.9) | 94.3 (86.6 to 97.9) | 22.7 (15.4 to 32.1) | 14.6 |
4 | cTnI | 3 | 87.0 (81.1 to 91.2) | 90.1 (85.0 to 94.0) | 98.0 (93.9 to 99.5) | 55.6 (39.3 to 70.7) | 12.2 |
8 | cTnI | 3 | 88.9 (83.5 to 92.7) | 90.1 (84.8 to 93.7) | 98.1 (94.1 to 99.5) | 58.5 (43.1 to 72.4) | 13.6 |
16 | cTnI | 3 | 89.3 (83.8 to 93.1) | 88.3 (82.7 to 92.4) | 98.0 (93.7 to 99.5) | 56.8 (42.0 to 70.5) | 14.7 |
24 | cTnI | 3 | 89.3 (83.4 to 93.3) | 85.7 (79.3 to 90.5) | 97.6 (92.5 to 99.4) | 55.6 (41.0 to 69.2) | 16.7 |
4 | Any marker | 3 | 88.0 (82.4 to 92.1) | 57.7 (50.4 to 64.7) | 97.0 (90.8 to 99.2) | 23.7 (16.1 to 33.3) | 13.0 |
8 | Any marker | 2 | 92.9 (88.2 to 95.8) | 54.0 (46.9 to 61.0) | 97.9 (92.0 to 99.6) | 24.5 (17.3 to 33.6) | 13.9 |
16 | Any marker | 2 | 92.9 (88.1 to 95.9) | 51.5 (44.3 to 58.5) | 97.8 (91.5 to 99.6) | 23.6 (16.6 to 32.5) | 13.9 |
24 | Any marker | 2 | 92.9 (88.0 to 95.9) | 46.6 (39.4 to 54.0) | 97.4 (90.9 to 99.5) | 23.2 (16.3 to 31.9) | 14.8 |
↵4-150 Patients sustaining an SCE despite negative marker concentrations up to and including this timepoint.
↵4-151 Probability of a patient avoiding any SCEs in hospital after a negative test result.
↵4-152 Probability of a patient experiencing an SCE in hospital after a positive test result.
↵4-153 Probability of a patient experiencing an SCE in hospital before applying the results of tests.
Post-test probability (%) of a patient suffering an SCE after a negative test = 100 − NPV.